<DOC>
	<DOCNO>NCT00220389</DOCNO>
	<brief_summary>This extension trial SP668 consist two phase : double-blind treatment open-label extension . The trial provide subject option long-term treatment sustain release ( SR ) fesoterodine ( SPM 907 ) ass long-term subject safety , tolerability efficacy . Double-Blind : Subjects remain either fesoterodine 4mg , 8mg 12mg depend dose assignment SP668 . Previous SP668 placebo subject receive fesoterodine 4mg . Open-Label : Subjects receive fesoterodine 8mg one time option reduce dose 4mg one time option increase 8mg . The primary variable focus long-term safety tolerability include observation assessment adverse event , residual urinary volume , laboratory parameter , change ECG , physical urological examination subject 's assessment treatment tolerance . Secondary efficacy variable include various parameter derive micturition diary , count subject dose choice throughout trial subject 's assessment treatment efficacy .</brief_summary>
	<brief_title>Two Phase Extension Trial SP668 Investigate Safety Tolerability Sustained Release Fesoterodine Subjects With Overactive Bladder : Double-Blind Phase Followed Open-Label Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Overactive bladder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>